Back to Portfolio
TSB is a Florida corporation that has acquired and is developing a novel topical antimicrobial technology. The technology allows for an unprecedented combination of safety, broad-spectrum antimicrobial efficacy against bacteria, viruses and fungi, and clinically significant persistence. Yet it is benign to the skin and the environment. The technology has already been proven safe and effective on humans via limited approvals in Europe.
The technology was originally licensed from Proctor &Gamble. It has been substantially improved and further developed by TSB. Key patents have been issued on the improvements. Due to a series of interactions with P&G during 2006 and 2007, TSB owes P&G substantially no royalties or milestone payments on the newer improved versions.
The technology has two principal uses. One is as a persistent hand sanitizer. The major hand hygiene markets are in healthcare (prevention of bacterial infections such as MRSA or VRE), and public heath (prevention of colds and flus). UK approvals for public health included prevention of colds and flus, with 99% kill of bacteria and virus on hands for up to 3 hours, while safe for use on children as well as adults. The other principal use is topical therapy for skin diseases such as acne vulgaris or inflammatory rosacea. Both of these markets are substantially over $1 billion globally.
The company presently has a written term sheet for a transaction with regard to topical therapeutics, and is in discussions concerning hand hygiene transactions.
- Industry: Biotech
- Location: Chicago, IL